Skip to main content
SpringerLink
Log in

Clinical trials

The rise of IL-2 therapy — a novel biologic treatment for SLE

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

An unmet need exists for more-effective and selective therapeutics in systemic lupus erythematosus. Advances in understanding of the pathogenetic mechanisms of this severe autoimmune disease have led to the clinical translation of low-dose IL-2 therapy, which primarily aims to restore the activity of regulatory T cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Humrich, J. Y. et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl Acad. Sci. USA 107, 204–209 (2010).

    Article  CAS  Google Scholar 

  2. von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407–1415 (2016).

    Article  CAS  Google Scholar 

  3. Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791–792 (2015).

    Article  Google Scholar 

  4. He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991–993 (2016).

    Article  CAS  Google Scholar 

  5. Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067–2077 (2011).

    Article  CAS  Google Scholar 

  6. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055–2066 (2011).

    Article  CAS  Google Scholar 

  7. European Medicines Agency. ClinicalTrialsRegister.eu https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001599-40 (2014).

  8. Humrich, J. Y. & Riemekasten, G. Restoring regulation — IL-2 therapy in systemic lupus erythematosus. Expert Rev. Clin. Immunol. http://dx.doi.org/10.1080/1744666X.2016.1199957 (2016).

  9. Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Hospital Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, Lübeck, 23538, Germany

    Jens Y. Humrich & Gabriela Riemekasten

Authors
  1. Jens Y. Humrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela Riemekasten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Riemekasten.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Humrich, J., Riemekasten, G. The rise of IL-2 therapy — a novel biologic treatment for SLE. Nat Rev Rheumatol 12, 695–696 (2016). https://doi.org/10.1038/nrrheum.2016.173

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.173

  • Springer Nature Limited

This article is cited by

Search

Navigation